Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autonomix MedicalAMIX +1.54%15 Price-to-Tangible-Book is 0.90 as of Aug. 22, 2026, which is 10% below its 10-year median of 1.00. GuruFocus rates AMIX with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 698 Medical Devices & Instruments companies, Autonomix Medical ranks better than 86.82% on this metric.
The historical rank and industry rank for Autonomix Medical's Price-to-Tangible-Book or its related term are showing as below:
AMIX'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.54 Med: 1 Max: 7.48
Current: 0.9
During the past 4 years, Autonomix Medical's highest Price to Tangible Book Ratio was 7.48. The lowest was 0.54. And the median was 1.00.
AMIX's Price-to-Tangible-Book is ranked better than 86.82% of 698
companies
in the Medical Devices & Instruments industry
Industry Median: 2.7
vs AMIX: 0.90
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Autonomix Medical Price-to-Tangible-Book Related Terms
Autonomix Medical Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Autonomix Medical's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMIX vs AEMD, NUMD, ESMC: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, Autonomix Medical's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autonomix Medical Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autonomix Medical's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Autonomix Medical's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Autonomix Medical (AMIX) has a Price-to-Tangible-Book of 0.90 as of Aug. 22, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Autonomix Medical and its competitors. This is 10% below median its historical median of 1.00. Over the past decade, Autonomix Medical's Price-to-Tangible-Book has ranged from 0.54 to 7.48. According to the industry distribution chart, Autonomix Medical ranks #92 out of 698 companies in the Medical Devices & Instruments industry, placing it in the top 13.2%.
Is Autonomix Medical's Price-to-Tangible-Book too high?
Autonomix Medical's current Price-to-Tangible-Book of 0.90 is 10% below median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 0.54 to a high of 7.48. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.70. Autonomix Medical's value of 0.90 is 66.7% below this industry median. Based on the distribution chart, Autonomix Medical ranks #92 out of 698 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Autonomix Medical has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Autonomix Medical's Price-to-Tangible-Book compare to AEMD and NUMD?
According to the Medical Devices & Instruments industry distribution chart, Autonomix Medical ranks #92 out of 698 companies for Price-to-Tangible-Book. This places Autonomix Medical in the top 13% of its industry — outperforming the majority of peers. The industry median Price-to-Tangible-Book is 2.70. Autonomix Medical's value of 0.90 is 66.7% below this benchmark. Historically, Autonomix Medical's own Price-to-Tangible-Book has ranged from 0.54 to 7.48 over the past decade. While the company's 10-year median is 1.00 vs. the industry median of 2.70, Autonomix Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.70, based on 698 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autonomix Medical's current Price-to-Tangible-Book of 0.90 is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Autonomix Medical and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autonomix Medical's current Price-to-Tangible-Book is 0.90, which is 10% below median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autonomix Medical stock overvalued right now?
Autonomix Medical (AMIX) has a current Price-to-Tangible-Book of 0.90. The current Price-to-Tangible-Book is 0.90, which is 10% below median its 10-year median of 1.00 and 66.7% below the Medical Devices & Instruments industry median of 2.70. Autonomix Medical's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Autonomix Medical (AMIX), the current Price-to-Tangible-Book is 0.90 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
15GF Score
Get the complete analysis for AMIX
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMIX has been successfully added to your 
